Image_2_FOXO3 Transcription Factor Regulates IL-10 Expression in Mycobacteria-Infected Macrophages, Tuning Their Polarization and the Subsequent Adaptive Immune Response.TIF
Alveolar Macrophages play a key role in the development of a robust adaptive immune response against the agent of Tuberculosis (TB), Mycobacterium tuberculosis (M.tb). However, macrophage response is often hampered by the production of IL-10, a potent suppressor of the host immune response. The secretion of IL-10 correlates with TB pathogenesis and persistence in host tissues. Concordantly, inhibition of IL-10 signaling, during BCG vaccination, confers higher protection against M.tb through a sustained Th1 and Th17 responses. Therefore, uncovering host effectors, underlying mycobacteria-induced expression of IL-10, may be beneficial toward the development of IL-10-blocking tools to be used either as adjuvants in preventive vaccination or as adjunct during standard treatment of TB. Here, we investigated the role of FOXO3 transcription factor in mycobacteria-induced secretion of IL-10. We observed that PI3K/Akt/FOXO3 axis regulates IL-10 expression in human macrophages. Knocking down of FOXO3 expression resulted in an increase of IL-10 production in BCG-infected macrophages. The gene reporter assay further confirmed the transcriptional regulation of IL-10 by FOXO3. In silico analysis identified four Forkhead binding motifs on the human IL-10 promoter, from which the typical FOXO3 one at position −203 was the major target as assessed by mutagenesis and CHIP binding assays. Further, we also observed a decrease in gene expression levels of the M1 typical markers (i.e., CD80 and CD86) in SiFOXO3-transfected macrophages while activation of FOXO3 led to the increase in the expression of CD86, MHCI, and MHCII. Finally, co-culture of human lymphocytes with siFOXO3-transfected macrophages, loaded with mycobacterial antigens, showed decreased expression of Th1/Th17 specific markers and a simultaneous increase in expression of IL-4 and IL-10. Taken together, we report for the first time that FOXO3 modulates IL-10 secretion in mycobacteria-infected macrophage, driving their polarization and the subsequent adaptive immune response. This work proposes FOXO3 as a potential target for the development of host-directed strategies for better treatment or prevention of TB.
History
References
- https://doi.org//10.15585/mmwr.mm6811a3
- https://doi.org//10.1016/j.micpath.2012.12.002
- https://doi.org//10.1038/nri3813
- https://doi.org//10.1016/j.molimm.2015.04.003
- https://doi.org//10.1155/2015/747543
- https://doi.org//10.1128/CMR.15.2.294-309.2002
- https://doi.org//10.1128/microbiolspec.TBTB2-0018-2016
- https://doi.org//10.1046/j.1365-2249.1999.00783.x
- https://doi.org//10.1172/JCI9918
- https://doi.org//10.1016/S0966-842X(00)01919-3
- https://doi.org//10.1165/rcmb.2010-0319OC
- https://doi.org//10.1046/j.1365-2567.2000.00018.x
- https://doi.org//10.1016/j.cellimm.2013.11.007
- https://doi.org//10.1111/j.1365-2567.2010.03402.x
- https://doi.org//10.1016/j.imbio.2016.05.011
- https://doi.org//10.1016/j.cyto.2016.06.018
- https://doi.org//10.4049/jimmunol.1202722
- https://doi.org//10.4049/jimmunol.181.8.5545
- https://doi.org//10.1002/eji.201040433
- https://doi.org//10.1038/mi.2011.7
- https://doi.org//10.1016/j.tube.2007.03.004
- https://doi.org//10.1371/journal.pone.0046481
- https://doi.org//10.4049/jimmunol.1201061
- https://doi.org//10.3389/fimmu.2017.01755
- https://doi.org//10.4049/jimmunol.171.2.717
- https://doi.org//10.1016/j.cellsig.2014.01.015
- https://doi.org//10.1371/journal.ppat.1003946
- https://doi.org//10.4049/jimmunol.1001861
- https://doi.org//10.1111/cmi.12298
- https://doi.org//10.3892/mmr.2015.4250
- https://doi.org//10.4135/9781412952644
- https://doi.org//10.1152/ajplung.00238.2017
- https://doi.org//10.1158/0008-5472.CAN-12-3767
- https://doi.org//10.4161/cbt.24342
- https://doi.org//10.1073/pnas.0904846106
- https://doi.org//10.3389/fcimb.2018.00327
- https://doi.org//10.3389/fimmu.2011.00043
- https://doi.org//10.1146/annurev-physiol-022516-034339
- https://doi.org//10.12703/P6-13
- https://doi.org//10.1007/s00018-015-1995-y
- https://doi.org//10.3389/fmicb.2017.02284
- https://doi.org//10.1016/j.cellimm.2008.03.002
- https://doi.org//10.1002/eji.201243217
- https://doi.org//10.1038/ncomms12748
- https://doi.org//10.1016/j.immuni.2004.06.016
- https://doi.org//10.1189/jlb.3A0514-251R
- https://doi.org//10.4049/jimmunol.1401754
- https://doi.org//10.1016/j.ajpath.2014.12.006
- https://doi.org//10.1158/1538-7445.AM2012-704
- https://doi.org//10.1038/sj.onc.1209086
- https://doi.org//10.1089/ars.2010.3414
- https://doi.org//10.1038/srep29297
- https://doi.org//10.1089/gtmb.2015.0090
- https://doi.org//10.1007/s10753-015-0217-y
- https://doi.org//10.1158/1078-0432.CCR-08-0124
- https://doi.org//10.1016/j.ccr.2010.10.031
- https://doi.org//10.1038/nature06345
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity